Form 4: Pfizer CEO Albert Bourla Awarded Stock Appreciation Rights
SEC Form 4 Filing
Pfizer's CEO, Albert Bourla, was granted stock appreciation rights that will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.
Summary
- On March 4, 2025, Albert Bourla, the Chairman and CEO of Pfizer Inc., was granted 1,487,296 stock appreciation rights (SARs).
- These SARs are subject to certain vesting requirements.
- The SARs will be settled in shares of Pfizer common stock on March 4, 2030, which is the fifth anniversary of the grant date.
- The exercise price of the SARs is $25.75.
- Following the transaction, Bourla directly owns 1,487,296 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock appreciation rights is a standard practice that aligns management's interests with shareholders, which is generally viewed favorably.
Positives
- The granting of stock appreciation rights to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's stock value.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting and settlement of the stock appreciation rights in 2030.
Industry Context
Granting stock appreciation rights is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock appreciation rights are a common form of executive compensation in large pharmaceutical companies like Johnson & Johnson, Merck, and AbbVie.
- These companies often use a mix of salary, bonus, stock options, and restricted stock units to incentivize their top executives.
- The specific terms and conditions of these grants, such as vesting schedules and performance metrics, can vary widely based on company performance and industry benchmarks.
Stakeholder Impact
- Shareholders may view this as a positive incentive for the CEO to improve company performance and increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the transaction: Albert Bourla was granted stock appreciation rights. |
| 03/04/2030 | Date the stock appreciation rights become exercisable and expire: The SARs will be settled in shares of Pfizer common stock. |
| 03/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.